ProCE Banner Activity

Considering a Claudin18.2-Targeted Agent in the Current Treatment Landscape for HER2-Negative Gastric Cancers

Clinical Thought

In this commentary, Gregory Botta, MD, PhD, evaluates claudin18.2 as a potential biomarker guiding patient care and placement of emerging claudin18.2-targeted agents within the therapeutic repertoire for advanced gastric and gastroesophageal cancers.

Released: June 14, 2023

Share

Faculty

Gregory Botta

Gregory Botta, MD, PhD

Clinical Professor of Medicine
Department of Medicine/Hematology & Oncology
University of California San Diego
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Astellas and Bristol Myers Squibb.

Astellas

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Gregory Botta, MD, PhD

Clinical Professor of Medicine
Department of Medicine/Hematology & Oncology
University of California San Diego
La Jolla, California

Gregory Botta, MD, PhD: consultant/advisor/speaker: Natera, TumorGen.